Obinutuzumab with Fludarabine/Cyclophosphamide or Bendamustine as First-Line Therapy for CLL


Obinutuzumab with Fludarabine/Cyclophosphamide or Bendamustine as First-Line Therapy for CLL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (2/13/14)
Brown JR et al. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): Results from the Phase 1b Galton trial (GAO4779g). Proc ASH 2013;Abstract 523.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at the UW Carbone Cancer Center in Madison, Wisconsin.